Microbiological spectrum of post-traumatic endophthalmitis unchanged

Article

The microbiological spectrum in patients with post-traumatic endophthalmitis has remained unchanged over the past 14 years, with Bacillus spp. still the most commonly found infecting organism, and vancomycin remaining the drug of choice for empiric coverage of gram-positive bacteria.

The microbiological spectrum in patients with post-traumatic endophthalmitis has remained unchanged over the past 14 years, with Bacillus spp. still the most commonly found infecting organism, and vancomycin remaining the drug of choice for empiric coverage of gram-positive bacteria. Researchers have noted, however, that the susceptibility of gram-negative bacteria to agents such as amikacin and ciprofloxacin has decreased by 10% to 15%, and to ceftazidime, increased by 10.5%.

Researchers conducted this retrospective review on 581 consecutive patients with culture-proven post-traumatic endophthalmitis at L.V. Prasad Eye Institute, India, from January 2006 to March 2013 to evaluate the microbiologic spectrum and antimicrobial susceptibility of isolates in post-traumatic endophthalmitis.

In all, 620 isolates were identified in these patients, comprised of 565 bacteria and 55 fungi. The most common of these isolates was Bacillus spp. (17.1%), followed by Streptococcus pneumonia (16.9%), and coagulase-negative Staphylococci (15.6%). Fourteen years earlier, these researchers reported that the most common bacteria found were Streptococcus spp. (21.6%) and gram-positive coagulase-negative micrococci (18.7%).

Gram-positive isolates were generally susceptible to vancomycin (98.2%). Gram-negative isolates were generally susceptible to gatifloxacin (92.9%); ofloxacin (89.4%); chloramphenicol (88.6%), although Pseudomonas isolates were often resistant; amikacin (83.5%); and ceftazidime (77.2%). According to the authors, 14 years ago, the most sensitive antibiotic for both gram-positive bacteria (95.12%) and gram-negative bacteria (100%) was ciprofloxacin.

To view the abstract of this study, published in the Journal of Ophthalmic Inflammation and Infection, click here.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.